Rawan G. Faramand, MD

In an interview, Rawan Faramand, MD, discussed her research on cost-effectiveness of graft modification to prevent GVHD in hematopoietic cell transplant.

Rawan Faramand, MD, discusses how reducing the cost of GVHD therapy could benefit health systems.

Rawan Faramand, MD, explains how a cost analysis supported Orca-T engineered graft by reducing the need for GVHD therapy vs standard prophylaxis.